Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generates frequent news flow around its efforts to develop and commercialize therapies for endocrine diseases and endocrine-related tumors. Company announcements highlight progress across its GPCR-targeted small-molecule portfolio, including regulatory milestones, clinical trial updates, capital markets activity, and corporate developments.
News coverage often focuses on PALSONIFY™ (paltusotine), Crinetics’ once-daily, oral somatostatin receptor type 2 agonist. Updates have included U.S. FDA approval for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, early launch metrics, and the design and enrollment status of the pivotal Phase 3 CAREFNDR trial in carcinoid syndrome associated with neuroendocrine tumors.
Investors and observers can also follow regular announcements on atumelnant, the company’s investigational ACTH receptor antagonist in late-stage development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Press releases describe Phase 2 results, the CALM-CAH Phase 3 trial design, biomarker changes such as reductions in androstenedione, and safety observations from both core studies and open-label extensions.
Additional news items cover the advancement of CRN09682, a nonpeptide drug conjugate targeting SST2-expressing tumors, including first-patient dosing in the Phase 1/2 BRAVESST2 trial and details of the trial’s dose-escalation and expansion phases. Crinetics also reports on preclinical programs like CRN12755 and CRN10329 through R&D Day presentations and conference abstracts.
Beyond R&D, Crinetics issues releases on public offerings of common stock, inducement equity grants under its 2021 Employment Inducement Incentive Award Plan, participation in major healthcare conferences, and executive transitions disclosed via Form 8-K. For users tracking CRNX, this news page provides a centralized view of the company’s clinical, regulatory, financial, and corporate announcements over time.
Crinetics Pharmaceuticals (NASDAQ: CRNX) has granted equity awards to 35 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The awards include 152,475 non-qualified stock options with an exercise price of $30.68 per share and 101,800 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals (NASDAQ: CRNX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial performance and provide a business update.
Participants can join via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with Conference ID: CRNXQ1. Alternatively, they can access the live webcast through the Events section of Crinetics' website. Participants are advised to connect 15 minutes before the call starts to ensure timely access. The webcast recording will be available later in the Investor Relations section of www.crinetics.com.
Crinetics Pharmaceuticals (CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. On April 10, 2025, the company's Compensation Committee awarded:
- Non-qualified stock options to purchase 124,950 shares with an exercise price of $26.85 per share
- 84,725 restricted stock unit (RSU) awards
These grants were made to 26 new non-executive employees as employment inducements. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest in four equal annual installments. All grants are subject to continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals (CRNX) announced two major regulatory milestones for paltusotine, its novel once-daily oral treatment for acromegaly. The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for review and granted Orphan Drug Designation (ODD) on February 27, 2025.
Paltusotine, the first oral selectively-targeted somatostatin receptor type 2 nonpeptide agonist, demonstrated success in two Phase 3 trials, meeting all primary and secondary endpoints. The trials showed statistically significant biochemical control and symptom improvement compared to placebo, with good tolerability.
The MAA submission includes data from 18 clinical trials. This follows the FDA's acceptance of the New Drug Application with a PDUFA date of September 25, 2025. The ODD status provides potential benefits including 10-year market exclusivity in the EU and reduced regulatory fees.
Crinetics Pharmaceuticals (CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company granted stock options to purchase 95,675 shares to fifteen new non-executive employees and 80,000 shares to one executive employee. Additionally, restricted stock unit (RSU) awards of 40,775 units were granted to sixteen non-executive employees and 52,000 units to one executive employee.
The stock options have an exercise price of $33.75 per share, matching CRNX's closing price on March 10, 2025. Both stock options and RSUs follow a four-year vesting schedule, with stock options vesting 25% after one year and the remainder monthly over 36 months, while RSUs vest in equal annual installments. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).